Becton Dickinson (BD) has acquired TVA Medical, a minimally invasive vascular access solutions maker, to expand its portfolio of products for chronic kidney disease patients.
TVA Medical’s product portfolio includes an endovascular arteriovenous (AV) fistula creation technology called everlinQ endoAVF System, which has secured the US Food and Drug Administration (FDA) De Novo authorisation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BD expects the everlinQ system to complement its range of dialysis catheters, drug-coated balloons, angioplasty balloons and endovascular stent graft products designed for end-stage renal disease (ESRD).
The system will enable BD to better help physicians and patients through a minimally invasive option to generate critical AV fistulas for haemodialysis procedures.
BD Peripheral Intervention worldwide president Steve Williamson said: “The addition of TVA Medical allows BD to provide another innovative device to physicians who treat patients suffering from chronic kidney disease requiring haemodialysis.
“This technology is highly complementary to our Peripheral Intervention offerings, and we will continue to bring new technologies to market that improve our category-leading ESRD portfolio.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe everlinQ endoAVF System features two flexible, magnetic catheters that are inserted via a small puncture into the ulnar artery and vein in the arm. The magnets in each catheter attract and pull the vessels together.
Upon confirmation of alignment, an electrode present in the venous catheter delivers radiofrequency energy in order to generate the connection between the artery and vein.
The procedure is said to reduce vessel and skin trauma when compared to standard fistula creation performed using open surgery.
TVA Medical co-founder Adam Berman said: “BD will enable us to deliver to physicians and patients what we believe is a highly-desirable and transformative endovascular technology as an integral part of a broader ESRD-focused portfolio of solutions.”
Financial details of the transaction have not been divulged.
